EXAGEN INC. (XGN) Spending and interest coverage
- R&D / revenue · 12 months: Value 9.09%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.12%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 9.09% | Research and development expense / revenue. Period ending 2026-06-30. $6.47M ÷ $71.12M × 100 ≈ 9.09% |
| Stock-based compensation / revenue · 12 months | 4.12% | Share-based compensation / revenue. Period ending 2026-06-30. $2.93M ÷ $71.12M × 100 ≈ 4.12% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 6.47M USD | Research and Development Expense |
| Revenue | 71.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.93M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -13.21M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.47M | $71.12M | $2.93M | $-13.21M | (m) | 9.09% | 4.12% | (m) | (m) |
| 2026-03-31 | $6.52M | $68.38M | $2.40M | $-14.12M | (m) | 9.54% | 3.50% | (m) | (m) |
| 2025-12-31 | $6.25M | $66.58M | $2.16M | $-14.07M | (m) | 9.39% | 3.24% | (m) | (m) |
| 2025-09-30 | $6.15M | $63.60M | $1.89M | $-12.48M | (m) | 9.67% | 2.97% | (m) | (m) |
| 2025-06-30 | $5.90M | $58.86M | $1.51M | $-14.04M | (m) | 10.03% | 2.57% | (m) | (m) |
| 2025-03-31 | $5.60M | $56.72M | $1.63M | $-14.00M | (m) | 9.87% | 2.87% | (m) | (m) |
| 2024-12-31 | $5.38M | $55.64M | $1.76M | $-13.64M | (m) | 9.66% | 3.17% | (m) | (m) |
| 2024-09-30 | $4.79M | $55.75M | $2.09M | $-15.40M | (m) | 8.60% | 3.75% | (m) | (m) |
| 2024-06-30 | $4.71M | $56.66M | $2.77M | $-15.81M | (m) | 8.32% | 4.88% | (m) | (m) |
| 2024-03-31 | $4.80M | $55.73M | $3.18M | $-18.13M | $2.25M | 8.61% | 5.71% | -8.07× | Reported |
| 2023-12-31 | $4.87M | $52.55M | $3.62M | $-22.84M | $2.33M | 9.26% | 6.88% | -9.78× | Reported |
| 2023-09-30 | $6.49M | $51.62M | $3.44M | $-32.18M | $2.40M | 12.57% | 6.66% | -13.44× | Reported |
| 2023-06-30 | $7.47M | $52.93M | $3.85M | $-34.93M | $2.46M | 14.12% | 7.28% | -14.22× | Reported |
| 2023-03-31 | $8.90M | $46.40M | $4.31M | $-44.08M | $2.49M | 19.18% | 9.30% | -17.72× | Reported |
| 2022-12-31 | $9.88M | $45.56M | $4.70M | $-46.05M | $2.45M | 21.68% | 10.32% | -18.81× | Reported |
| 2022-09-30 | $9.38M | $45.41M | $5.30M | $-37.81M | $2.46M | 20.65% | 11.67% | -15.37× | Reported |
| 2022-06-30 | $8.73M | $44.30M | $5.35M | $-35.15M | $2.52M | 19.72% | 12.07% | -13.94× | Reported |
| 2022-03-31 | $7.94M | $48.11M | $5.19M | $-28.18M | $2.58M | 16.50% | 10.79% | -10.93× | Reported |
| 2021-12-31 | $7.24M | $48.30M | $4.73M | $-24.07M | $2.63M | 14.98% | 9.79% | -9.17× | Reported |
| 2021-09-30 | $6.20M | $48.28M | $4.37M | $-20.57M | $2.64M | 12.84% | 9.05% | -7.80× | Reported |
| 2021-06-30 | $5.48M | $46.80M | $3.81M | $-17.86M | $2.61M | 11.70% | 8.15% | -6.85× | Reported |
| 2021-03-31 | $4.34M | $42.98M | $3.17M | $-15.53M | $2.58M | 10.09% | 7.39% | -6.02× | Reported |
| 2020-12-31 | $3.57M | $41.98M | $2.69M | $-15.19M | $2.56M | 8.50% | 6.42% | -5.92× | Reported |
| 2020-09-30 | $2.97M | $39.52M | $2.36M | $-15.28M | $2.68M | 7.51% | 5.98% | -5.69× | Reported |
| 2020-06-30 | $2.46M | $39.19M | $1.63M | $-13.65M | $2.95M | 6.27% | 4.15% | -4.63× | Reported |
| 2020-03-31 | $2.30M | $40.71M | $991.00K | $-12.65M | $3.22M | 5.64% | 2.43% | -3.93× | Reported |
| 2019-12-31 | $2.18M | $40.39M | $572.00K | $-9.30M | $3.49M | 5.39% | 1.42% | -2.66× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $2.13M | $32.44M | $114.00K | $-4.88M | $2.87M | 6.55% | 0.35% | -1.70× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |